Upgrade to SI Premium - Free Trial

BioAge Labs (BIOA)

9.59 +0.09 (0.95%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

Leqembi Iqlik® for initiation treatment launched in the US August 24, 2026 8:40 AM - PR NewsWire BioArctic and Mesenkia enter oncology research collaboration August 19, 2026 5:43 AM - PR NewsWire Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST August 19, 2026 2:55 AM - PR NewsWire Form SCHEDULE 13G/A BioAge Labs, Inc. Filed by: Cormorant Asset Management, LP August 14, 2026 2:01 PM - SEC Filing BioAmber (BIOA) Reports Q2 Loss of $0.58 August 5, 2026 6:21 PM - StreetInsider Form 10-Q BioAge Labs, Inc. For: Jun 30 August 5, 2026 5:01 PM - SEC Filing Form 8-K BioAge Labs, Inc. For: Aug 05 August 5, 2026 4:55 PM - SEC Filing BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates August 5, 2026 4:50 PM - Globe NewsWire BioAge Labs Inc (BIOA) PT Lowered to $21 at Jefferies July 31, 2026 1:10 PM - StreetInsider Monte Rose, BioAge Labs Crushed Following NVO Results July 31, 2026 7:40 AM - StreetInsider Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026 July 29, 2026 6:28 AM - PR NewsWire More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 July 14, 2026 11:39 AM - PR NewsWire FDA clears Leqembi Iqlik subcutaneous shot as Alzheimer's start dose July 13, 2026 10:38 PM - StreetInsider FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease July 13, 2026 10:38 PM - PR NewsWire New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease July 13, 2026 12:03 AM - PR NewsWire Form 4 BioAge Labs, Inc. For: Jun 29 Filed by: Barton Shane July 1, 2026 4:27 PM - SEC Filing Form 144 BioAge Labs, Inc. Filed by: Barton Shane June 30, 2026 4:22 PM - SEC Filing New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026 June 30, 2026 2:45 AM - PR NewsWire Form 144 BioAge Labs, Inc. Filed by: Barton Shane June 29, 2026 4:35 PM - SEC Filing BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology June 22, 2026 1:53 AM - PR NewsWire BioAge Labs begins Phase 2 trial of NLRP3 inhibitor BGE-102 June 16, 2026 8:00 AM - StreetInsider BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk June 16, 2026 8:00 AM - Globe NewsWire Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: Pande Vijay Satyanand June 12, 2026 4:37 PM - SEC Filing Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: Hemrajani Rekha June 12, 2026 4:36 PM - SEC Filing Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: HEALY JAMES June 12, 2026 4:34 PM - SEC Filing Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: ENRIGHT PATRICK G June 12, 2026 4:33 PM - SEC Filing Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: Davidson Michael H. June 12, 2026 4:32 PM - SEC Filing Form 4 BioAge Labs, Inc. For: Jun 10 Filed by: GARNIER JEAN PIERRE June 12, 2026 4:29 PM - SEC Filing Form 8-K BioAge Labs, Inc. For: Jun 10 June 12, 2026 8:00 AM - SEC Filing Full Article List